ADMA Biologics, Inc.
$9.11
$0.16 (+1.79%)
$8.81Day Range$9.13
Key Statistics
Market Cap
$2.00B
Shares Outstanding
224.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 17, 2013
Round Lot
100
Locale
US
Trading Data
Day Open
$8.92
Day High
$9.13
Day Low
$8.81
Volume
11.40M
VWAP
$9.07
Prev Close
$8.95
Transactions
--
Acc. Volume
--
About ADMA Biologics, Inc.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836647 employeesC/O ADMA BIOLOGICS, INC., RAMSEY, NJ, 07446(201) 478-5552IPO Oct 17, 2013US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001368514
- Composite FIGI
- BBG002NCK5M5
- Share Class FIGI
- BBG002NCK5N4
- Ticker Root
- ADMA
- SIC Code
- 2836
About ADMA Biologics, Inc. (ADMA) Stock
ADMA Biologics, Inc. (ADMA) closed the 2026-09-18 session at $9.11, up 1.79% versus the previous close (+0.16). The stock opened at $8.92 and traded between $8.81 and $9.13 during that session. Session trading volume was 11.4M shares. The volume-weighted average price (VWAP) is $9.07.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
ADMA Biologics, Inc. has a market capitalization of $2.00 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. ADMA is listed on the XNAS exchange. The company employs approximately 647 people. ADMA Biologics, Inc. is headquartered in RAMSEY, NJ. The recorded listing date is 2013-10-17.
On this page you can find market ADMA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.